In:
British Journal of Haematology, Wiley, Vol. 182, No. 5 ( 2018-09), p. 701-704
Abstract:
Erythropoiesis‐stimulating agents ( ESA s) were combined with ruxolitinib in 59 anaemic myelofibrosis patients (93% with Dynamic International Prognostic Scoring System [ DIPSS ] intermediate‐2/high risk; 52·5% transfusion‐dependent). Anaemia response ( AR ) rate was 54% and 76% of patients responded at 5 years. A further 15% displayed minor improvement in anaemia and 78% of patients reduced spleen size. Endogenous erythropoietin levels 〈 125 u/l correlated with a higher AR rate (63% vs. 20%, P = 0·008). No thrombotic events or other toxicities occurred. Overall survival was 62% at 4 years, influenced by DIPSS and transfusion dependency. ESA s seem effective in improving anaemia in ruxruxolitinib‐treated myelofibrosis patients.
Type of Medium:
Online Resource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2018.182.issue-5
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
1475751-5
Permalink